Standardised incidence ratios for cancers occurring in patients treated with anakinra
| Site of malignancy | Observed | Expected* | SIR | 95% CI |
|---|---|---|---|---|
| *Expected numbers of cases estimated using 1992–2000 SEER database adjusted for the age, sex, and race of cohort receiving anakinra. | ||||
| †Excludes malignancies that are not included in the SEER database (basal and squamous cell carcinomas of the skin and all in situ malignancies other than those of the bladder). | ||||
| ‡Combines all other SEER major organ system categories. | ||||
| CI, confidence interval; SIR, standardised incidence ratio, calculated as observed/expected. | ||||
| All sites† | 17 | 20.58 | 0.83 | 0.48 to 1.32 |
| Oral cavity and pharynx | 1 | 0.44 | 2.26 | 0.06 to 13.00 |
| Digestive system | 2 | 3.49 | 0.57 | 0.07 to 2.07 |
| Respiratory system | 1 | 3.19 | 0.31 | 0.01 to 1.75 |
| Malignant melanoma | 4 | 0.73 | 5.48 | 1.49 to 14.00 |
| Breast | 3 | 4.70 | 0.64 | 0.13 to1.86 |
| Female genital system | 1 | 1.85 | 0.54 | 0.01 to 3.02 |
| Urinary system | 2 | 1.23 | 1.63 | 0.20 to 5.89 |
| Lymphoma | 3 | 0.81 | 3.71 | 0.77 to 11.00 |
| Other‡ | 0 | 4.13 | 0.00 | 0.00 to 0.89 |